Guggenheim Initiates Coverage On Solid Biosciences with Buy Rating, Announces Price Target of $26
Benzinga Newsdesk 7 months ago
NewsPrice TargetInitiationAnalyst Ratings
Guggenheim analyst Debjit Chattopadhyay initiates coverage on Solid Biosciences (NASDAQ:SLDB) with a Buy rating and announces Price Target of $26.
Guggenheim analyst Debjit Chattopadhyay initiates coverage on Solid Biosciences (NASDAQ:SLDB) with a Buy rating and announces Price Target of $26.